Millendo Therapeutics Inc (NASDAQ:MLND) has received an average rating of “Buy” from the nine ratings firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $25.29.
MLND has been the topic of a number of analyst reports. Citigroup set a $12.00 target price on shares of Controladora Vuela Co Avcn SA CV and gave the stock a “buy” rating in a report on Monday, July 15th. Zacks Investment Research raised shares of Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Tuesday. Oppenheimer initiated coverage on shares of Neurocrine Biosciences in a report on Tuesday. They set an “outperform” rating and a $100.00 target price on the stock. CIBC decreased their target price on shares of Stuart Olson from C$5.00 to C$4.00 in a report on Tuesday. Finally, ValuEngine lowered shares of Welbilt from a “hold” rating to a “sell” rating in a report on Wednesday, June 12th.
Shares of MLND stock traded down $0.14 during trading on Monday, reaching $10.51. 30,144 shares of the company’s stock traded hands, compared to its average volume of 102,244. The company has a market capitalization of $142.56 million, a P/E ratio of -0.60 and a beta of 2.61. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.83 and a quick ratio of 7.83. The stock has a 50-day moving average price of $12.56. Millendo Therapeutics has a 1 year low of $6.77 and a 1 year high of $17.34.
Millendo Therapeutics (NASDAQ:MLND) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($0.78) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.08). Equities research analysts forecast that Millendo Therapeutics will post -3.27 EPS for the current year.
A number of institutional investors have recently bought and sold shares of the stock. Great Point Partners LLC bought a new position in shares of Millendo Therapeutics in the 4th quarter worth $10,240,000. Worth Venture Partners LLC bought a new position in shares of Millendo Therapeutics in the 4th quarter worth $206,000. BlackRock Inc. bought a new position in shares of Millendo Therapeutics in the 4th quarter worth $203,000. Tibra Equities Europe Ltd bought a new position in shares of Millendo Therapeutics in the 1st quarter worth $303,000. Finally, Private Advisors LLC increased its holdings in shares of Millendo Therapeutics by 9.1% in the 1st quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock worth $229,000 after buying an additional 1,279 shares during the last quarter. 44.07% of the stock is currently owned by institutional investors and hedge funds.
Millendo Therapeutics Company Profile
Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.
Featured Article: Why are analyst ratings important in trading stocks?
Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.